Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Eribulin mesylate exerts specific gene expression changes in pericytes and shortens pericyte-driven capillary network in vitro

1 Jan 2014

Abstract excerpt

BACKGROUND: Eribulin mesylate is a synthetic macrocyclic ketone analog of the marine sponge natural product halichondrin B. Eribulin is a tubulin-binding drug and approved in many countries worldwide for treatment of certain patients with advanced breast cancer. Here we investigated antiproliferative and antiangiogenic effects of eribulin on vascular cells, human umbilical vein endothelial cells (HUVECs) and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiogenesis and VEGF in Cancer
Share to Cancer, Hypoxia, and Metabolism
Share to Cancer Treatment and Pharmacology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24581301
DOI: 10.1186/2045-824x-6-3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Eribulin mesylate exerts specific gene expression changes in pericytes and shortens pericyte-driven capillary network in vitroPMID 24581301Read ↗

Selective tubulin-binding drugs induce pericyte phenotype switching and anti-cancer immunity.Semantic proximity Read ↗

Molecular targets of vortioxetine mediating glioblastoma suppression revealed by gene and protein network analyses and molecular docking simulationsSemantic proximity Read ↗

Diverse microtubule-destabilizing drugs induce equivalent molecular pathway responses in endothelial cellsSemantic proximity Read ↗

Real-world data of eribulin in advanced and pretreated HER2-negative breast cancer in a Spanish comprehensive cancer centerSemantic proximity Read ↗

Gene expression profiling of DMU-212-induced apoptosis and anti-angiogenesis in vascular endothelial cellsSemantic proximity Read ↗

Integrating Vascular Phenotypic and Proteomic Analysis in an Open Microfluidic Platform.Semantic proximity Read ↗

Breast cancer derived exosomes promoted angiogenesis of endothelial cells in microenvironment via circHIPK3/miR-124-3p/MTDH axisSemantic proximity Read ↗

A genome-wide RNAi screen identifies novel targets of neratinib sensitivity leading to neratinib and paclitaxel combination drug treatmentsSemantic proximity Read ↗

Inducers of the endothelial cell barrier identified through chemogenomic screening in genome-edited hPSC-endothelial cellsSemantic proximity Read ↗

Paracrine signalling in breast cancer: Insights into the tumour endothelial phenotype.Semantic proximity Read ↗

Determination of Usnic Acid Responsive miRNAs in Breast Cancer Cell LinesSemantic proximity Read ↗

The coumarin derivative X6632 is a pan-ID protein inhibitor that suppresses tumor growth by targeting cancer cells and the tumor-associated microvasculatureSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.